Ethnic differences in adiposity and diabetes risk - insights from genetic studies by Yaghootkar, Hanieh
doi: 10.1111/joim.13082
Ethnic differences in adiposity and diabetes risk – insights
from genetic studies
H. Yaghootkar1,2,3 , B. Whitcher2, J. D. Bell2 & E. L. Thomas2
From the 1Genetics of Complex Traits, University of Exeter Medical School, Royal Devon & Exeter Hospital, Exeter; 2School of Life Sciences,
College of Liberal Arts and Science, University of Westminster, London, UK; and 3Division of Medical Sciences, Department of Health
Sciences, Lulea University of Technology, Lulea, Sweden
Content List – Read more articles from the symposium: “Obesity and Type 2 Diabetes: Understanding the Role of Ethnicity”.
Abstract. Yaghootkar H, Whitcher B, Bell JD, Thomas
EL (Royal Devon & Exeter Hospital, Exeter;
University of Westminster, London, UK; and
University of Technology, Lulea, Sweden). Ethnic
differences in adiposity and diabetes risk – insights
from genetic studies (Review Symposium). J Intern
Med 2020; 288: 271–283.
Type 2 diabetes is more common in non-Europeans
andstartsatayoungerageandat lowerBMIcut-offs.
This review discusses the insights from genetic
studies about pathophysiological mechanisms
which determine risk of disease with a focus on the
role of adiposity and body fat distribution in ethnic
disparity in risk of type 2 diabetes. During the past
decade, genome-wide association studies (GWAS)
have identifiedmore than400genetic variants asso-
ciated with the risk of type 2 diabetes. The Eurocen-
tric nature of these genetic studies has made them
less effective in identifying mechanisms that make
non-Europeans more susceptible to higher risk of
disease. One possible mechanism suggested by
epidemiologicalstudiesistheroleofethnicdifference
in body fat distribution. Using genetic variants
associated with an ability to store extra fat in a safe
place, which is subcutaneous adipose tissue, we
discuss how different ethnic groups could be genet-
ically less susceptible to type 2 diabetes by develop-
ing amore favourable fat distribution.
Keywords: type 2 diabetes, obesity, ethnicity, genet-
ics.
Introduction
Type 2 diabetes is a common disease worldwide,
but its prevalence varies widely across different
ethnic groups. The prevalence of diabetes in the
USA, according to self-reported ethnicity and self-
reported physician-diagnosed diabetes, ranges
from 17.7% in white European individuals to
22.5% in Asians, 30.6% in Hispanics and Africans,
and 45.2% in American Indians/Alaska Natives in
adults ≥ 75 years of age [1]. This diversity is even
evident in ethnic subgroups, where Indians have
the highest risk of disease (38.8%) amongst Asians,
and Mexicans have the highest prevalence (33.4%)
amongst Hispanics [2]. In addition to ethnic dis-
parity in prevalence, type 2 diabetes starts at a
younger age and at lower BMI cut-offs in Africans
and Asians than in white Europeans [3].
Although type 2 diabetes is typically diagnosed as
high levels of blood glucose levels, it is a collection
of metabolic derangements, some of which may
play a causal role in the ethnic differences in
prevalence of type 2 diabetes, including body fat
distribution, adipose tissue function and different
levels of insulin secretion and insulin sensitivity
(Fig. 1) which may be involved in the ethnic differ-
ences. The integration of extensive multidimen-
sional data on glycaemic phenotypes, abdominal
MRI scans of fat distribution and metabolic
biomarkers in combination with dense and accu-
rate genetic data has facilitated the understanding
of diverse disease mechanisms.
Study of ethnic differences in type 2 diabetes risk
could lead us to a better understanding of disease
mechanisms and eventually have implications for
clinical and public health efforts in targeting the
prevention of the disease especially in the era of
precisionmedicine. In this review,wewill discuss the
insights from genetic studies about pathophysiolog-
icalmechanismswhichdetermineriskofdiseasewith
a focus on the role of adiposity and body fat distribu-
tion in ethnic disparity in risk of type 2 diabetes.
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Review Symposium
Insights from genetic studies of type 2 diabetes
During the past decade, genome-wide association
studies (GWAS) have dissected the genetic archi-
tecture of type 2 diabetes in a hypothesis-free way.
In these studies, by comparing frequencies of
alleles between cases and healthy controls, more
than 400 genetic variants known as Single Nucleo-
tide Polymorphisms (SNPs) have been implicated in
the risk of type 2 diabetes [4]. These variants have
unravelled diverse biological mechanisms and
pathways involved in the pathogenicity of the
disease. The majority of these variants modulate
the risk through insulin secretion, either through
direct effects on islet function (e.g. KCNJ11) or islet
development (HNF1A, WFS1) or indirectly through
impact on incretin signalling (GLP1R) [5]. In con-
trast, a handful of type 2 diabetes associated loci
seem to primarily operate through insulin resis-
tance (PPARG, IRS1), adipogenesis (KLF14, PPARG)
and obesity (FTO) [5].
The discovery from GWAS of type 2 diabetes in
populations of non-Europeans, including South
Asians [6], East Asians [7,8], Hispanics/Latinos [9-
11], Africans [12-15] as well as some isolated
populations [16,17], has been successful in iden-
tifying ancestry-specific signals that are rare or
nonexistent in most populations but have large
effects in their studied populations. These GWASs
have helped identify novel risk loci, for example,
the KCNQ1 locus in the Japanese population [18],
ZRANB3 locus in Africans [19], SLC16A11 in Mex-
icans [11], ZFAND3 in East Asians [7] (Table 1).
Studies of relatively isolated populations have
provided examples of common variants with large
effects that are very rare in other populations.
Examples include a CREBRF variant in Samoans
[20], an HNF1A variant in Oji-Cree Indians [16] and
ITGA1 [21] and TBC1D4 variants [17] in the
Greenlandic Inuit (Table 1). The last example,
TBC1D4 variants, accounts for 10% of diabetes in
Greenlandic Inuit where 14% of people carry at
least one copy of the risk allele and those who have
two copies, are at tenfold higher risk of type 2
diabetes.
The other unique opportunity provided by genetic
studies of non-European populations is the
Fig. 1 The McCarthy ‘palette’ model of type 2 diabetes. In this model the colour of each individual is painted based on
contribution of the ‘base colours’ representing the various pathophysiological processes underlying type 2 diabetes.
Adapted from McCarthy [96].
Ethnic differences in adiposity and diabetes / H. Yaghootkar et al.
272 ª 2020 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication
Journal of Internal Medicine, 2020, 288; 271–283
identification of new drug targets. A genetic study
of Mexicans identified a novel protective variant in
IGF2 associated with 20% lower risk of type 2
diabetes [22]. The frequency of the protective allele
is 17% in the Mexican population but the variant is
rare in Europeans. Functional studies showed that
the protective allele is associated with lower
expression of IGF2 in human liver and adipose
tissue but has no effect on other tissues and no
association with other traits [22]. These findings
suggest that any compound which inhibits the
expression of this gene in relevant tissues has
potential as a new therapeutic drug for type 2
diabetes beyond Mexican population with no major
adverse effects on health.
Ethnic-specific genetic predisposition to type 2 diabetes
An alternative explanation for ethnic differences in
diabetes risk relates to genetic predisposition. A
different degree of genetic predisposition has been
shown previously to explain ethnic differences in
the risk of some nondiabetic disease outcomes; for
example, genetic studies have shown that variants
in 8q24 [23] and variants in MYH9 [24] contribute
to excess disease risk of prostate cancer and
kidney disease, respectively, in African Americans
compared to European Americans. Is there any
ethnic-specific genetic variation which could
explain the excess risk of type 2 diabetes in that
ethnic group?
Novel loci identified in ancestry-specific GWASs
have been very successful in providing novel
mechanistic insights and potential drug targets
for type 2 diabetes; however, they have not suc-
cessfully explained ethnic disparities in type 2
diabetes risk. The majority of genetic variants
associated with the risk of type 2 diabetes are
common and have similar effect sizes and frequen-
cies across ethnic groups [25-28]. Studies which
looked at the role of genetic predisposition in
ethnic-specific type 2 diabetes risk are based on
comparisons of genetic risk scores between differ-
ent ethnic groups. These genetic risk scores are
defined as the number of risk alleles across mul-
tiple established type 2 diabetes variants. Studies
have shown that African populations have the
greatest genetic risk, Europeans an intermediate
risk, whilst East Asians and American Indians
have the lowest risk [29-32]. This pattern may
partially explain some of the differences between
Africans and Europeans but fails to explain the
high prevalence of type 2 diabetes in American
Indians [32].
The major limitation in the design of these studies
is that they all have used genetic variants solely
derived from GWASs of Europeans which have
minimal ability to capture risk in individuals of
non-European origin. Due to different linkage
disequilibrium patterns across different popula-
tions, the correlation between established variants
and true causal variants are different between
Europeans and other populations. Furthermore,
these studies have used a small number of estab-
lished type 2 diabetes genetic markers that may
not be the true causal variants. The true causal
variants in these genetic regions may be more
common in frequency and/or have larger effects
Table 1. Examples of genetic variants identified in GWAS of type 2 diabetes in populations of non-Europeans
SNP ID
Mapped
gene Function Population
Effect on risk of type 2
diabetes in odds ratio
rs2283228 KCNQ1 Insulin secretion Japanese 1.26
chr2:136064024 ZRANB3 b-cells production or maintenance Africans 1.05
rs13342232 SLC16A11 hepatic lipid metabolism Mexicans 1.29
rs9470794 ZFAND3 b-cells function East Asians 1.16
rs373863828 CREBRF Adipogenesis Samoans 0.6
rs137853240 HNF1A b-cells production or maintenance Oji-Cree
Indians
2
rs870992 ITGA1 b-cells function Greenlandic
Inuit
2.79
rs61736969 TBC1D4 Regulates the insulin-dependent uptake of
glucose by skeletal muscle and fat tissues)
Greenlandic
Inuit
10.3
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than the index signals in non-European popula-
tions. The other limiting factor is power. The
established type 2 diabetes variants have very
modest odds ratios (1.1–1.3 per copy of the risk
allele). Therefore, their discovery required studies
of more than tens of thousands of cases and
controls to reach genome-wide significance in
European populations. Available sample sizes in
non-European studies have provided limited power
to detect these modest effects. Finally, the
increased prevalence of type 2 diabetes in non-
European populations could be the result of envi-
ronmental factors or genetic factors that remain
largely unidentified.
The role of variation in adiposity in susceptibility to type 2
diabetes, evidence from observational studies
Epidemiological studies have highlighted the dif-
ferences in anthropometry and body composition
as one possible mechanism for ethnic differences
in susceptibility to obesity-related metabolic disor-
ders including type 2 diabetes [33,34]. This argu-
ment is based on a number of observational
differences between ethnic groups which are pre-
sented here.
South Asians have been reported to have higher
waist circumference, waist-to-hip ratio [35] and
5-7% higher total body fat at any given BMI [36]
compared to white Europeans. This elevated
central adiposity in South Asians has been linked
to greater risk of developing type 2 diabetes,
insulin resistance and cardiovascular disease at a
lower BMI compared to white Europeans [37].
Lean mass and the lean-to-fat-mass ratio are also
lower in South Asians compared to white Euro-
peans and East Asians. The combination of low
muscle mass and high truncal fat (estimated by
high subscapular skinfold thickness) has been
detected in South Asian newborns and is pre-
sumed to predispose to insulin resistance later in
life [38].
East Asians have lower prevalence of obesity,
although fat distribution appears to be less favour-
able. Data from Chinese, Japanese, Korean, Tai-
wanese and Filipino populations show that in both
sexes, the per cent of abdominal adiposity is higher
in East Asians compared to white Europeans. This
pattern of fat distribution seems to arise early since
prepubescent East Asian boys and girls have lower
gynoid fat and fat in extremities compared to white
children at pubertal age [39-41].
The prevalence of obesity and morbid obesity is
particularly high in Africans, but they develop a
favourable fat distribution in comparison to white
Europeans in spite of the higher disease risk [42].
Individuals of West African descent have higher
muscle mass and less central adiposity compared
to white Europeans, yet have a higher risk of
developing hypertension, stroke and type 2 dia-
betes [43,44]. The greater susceptibility to develop
metabolic diseases in Africans therefore appears to
be at odds with a favourable profile of less central
fat mass and higher muscle mass. African Amer-
icans have a larger risk than whites at BMI of
22 kg m2 and an equivalent risk for both groups
at BMI of 32 kg m2 [45]. Thus, the impact of BMI
on diabetes risk seems to be different for African
Americans and white Europeans.
Adiposity per se does not explain the excess risk for type 2
diabetes
Data from observational studies indicate that
although different ethnic groups have different
degrees of adiposity, these differences do not
explain the excess risk. For example, nondiabetic
African Americans and Hispanics have higher
insulin resistance compared with nondiabetic
white Europeans after adjusting for adiposity
measures, suggesting that higher insulin resis-
tance, independent of obesity, may be in part
responsible for the higher prevalence of diabetes
in these groups [46]. Other studies show African
American nondiabetic children and adults exhibit
hyperinsulinaemia due to a combination of higher
insulin secretion and lower rates of insulin clear-
ance [47-51] compared to other ethnicities [47,52-
56] which is not explained by insulin resistance
[47,53]. Hyperinsulinaemic feature in black Afri-
can and whether it precedes insulin resistance or is
merely a compensatory mechanism is reviewed in
an accompanying paper by Goedecke and Olsson.
Evidence from Asian ethnic groups is different
suggesting that an insulin secretory defect may
play a more important role than insulin resistance
in the pathogenesis of type 2 diabetes [57-59]. For
example, impaired pancreatic b-cell function has
been shown to be the driving force behind the high
prevalence of diabetes in Asian Indians compared
to white Europeans, Africans and Hispanics [60].
Studies of beta-cell function amongst individuals of
Chinese, Malay and Asian–Indian ethnicity living
in Singapore demonstrated early-phase insulin
secretion trended highest amongst Chinese,
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followed by Asian Indians and was the lowest
amongst Malays. However, Chinese are the most
insulin sensitive whilst Asian Indians are the least
insulin sensitive [61].
BMI, body fat % and waist-to-hip ratio are poor predictors for
adiposity, fat distribution and metabolic risk
Previous studies assessing the impact of ethnicity
on body fat composition and risk of type 2 diabetes
most often used indirect measurements of adipos-
ity, including BMI, waist-to-hip ratio and/or mea-
sures of fat mass and lean mass derived from
bioelectrical impedance. These measures are
unable to differentiate between anatomically dis-
tinct fat depots. Accurate phenotyping of anthro-
pometry and body fat distribution using medical
imaging for precise mapping and quantification of
body adiposity is therefore required to determine
their potential contribution to ethnic differences in
diabetes risk.
It is well established that BMI has numerous
limitations; it cannot distinguish between fat and
lean mass and is not indicative of body fatness.
This may explain why ~ 50% of overweight
and ~ 30% of obese individuals, based on BMI,
are free from any obvious sign of metabolic and
cardiovascular complications [62]. The problem
with waist circumference or waist-to-hip ratio is
that they cannot distinguish between visceral and
abdominal subcutaneous fat depots. Figure 2
illustrates how two people with same BMI or waist
circumference, same age and gender can have very
different levels of subcutaneous, visceral and liver
fat and therefore, different disease risk.
What MRI measures add to the evidence?
Not all fat depots are equally detrimental for
health. A different anatomical location makes a
substantial difference. Visceral fat and ectopic fat
accumulation in or around the liver, pancreas and
muscles are causally related to insulin resistance,
impaired glucose homoeostasis and type 2 dia-
betes. The divergent regulatory functions of vis-
ceral and subcutaneous fat depots may be the
reason why some people are relatively protected
against cardiometabolic diseases, especially type 2
diabetes.
There is limited data available regarding specific
patterns of body fat distribution and liver fat
content in different ethnic groups. In general,
observational data suggests that South Asians
not only accumulate high amounts of adipose
tissue, but also demonstrate a preferential central
fat distribution with larger visceral depots in com-
parison to white European subjects matched for
waist circumference [63,64] and also have higher
levels of ectopic liver fat both postnatally [65] and
in adulthood [66] compared with Europeans. CT
and MRI studies show that visceral fat is higher in
East Asians compared to Europeans [67-69] and
they show the most deleterious abdominal fat
distribution amongst white Europeans, Caribbean
Africans, Hispanics and Southeast Asians, [70].
A number of studies have pointed out a potential
role for deep abdominal subcutaneous fat in
metabolic abnormalities [71]. However, most imag-
ing studies of body adiposity do not differentiate
between superficial and deep abdominal subcuta-
neous fat [72]. This is mainly due to the fact that it
is not always feasible to distinguish between these
depots in most volunteers. However, in the studies
where this has been achieved, African women show
larger superficial, and similar deep subcutaneous
adipose tissue depots compared to white Euro-
peans [73]. Comparing individuals of white Euro-
pean, Chinese, South Asian and Native American,
fat in the deep compartment was higher in Native
Americans and South Asians, and lower in Chinese
[70,74].
Another potentially important ectopic fat depot is
the intramuscular fat, which has been shown to be
higher in African than in white Europeans and
East Asian individuals [75]. There is evidence that
Hispanic and African Americans have a tendency
for higher lipid accumulation in skeletal muscle
compared to white Europeans, independent of
their overall body size, obesity or higher visceral
and/or subcutaneous adipose tissue [76]. How-
ever, a recent study of healthy white European and
black west African men reported similar levels of
muscle fat in both groups [77].
It should be pointed out that in all the studies
reporting ethnic differences in fat distribution, the
classification of individuals into ethnic groups of
white Europeans, Africans, and East and South
Asian origin has been overly simplistic. Further-
more, there is evidence that differences in adiposity
and fat distribution exist within ethnic subpopu-
lations, for example, Kenyan and Chinese [78,79].
Another limitation which makes the current evi-
dence less conclusive is that it is difficult to rule
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out the role of selection bias in all these studies.
Participants may not be representative of their
ethnic groups and may have other factors associ-
ated with less or more favourable metabolic profile.
To overcome these limitations, we analysed data
from UK Biobank study [80] where we had access
to adiposity measures including detailed pheno-
typing of fat depots from MRI scans in much larger
sample size than previously reported. The avail-
ability of genetic data made it possible for us to
identify ethnicity of participants who genetically
clustered with white Europeans or Africans or
South Asians. We did not observe any differences
in visceral fat, liver fat or intramuscular fat,
adjusted for age and BMI, between South Asians
and white Europeans or Africans. The comparison
of same phenotypes in another UK-based cohorts
was consistent with results from UK Biobank
(Alenaini et al, unpublished). This observation
could indicate that ethnic variations in suscepti-
bility to cardiometabolic disease may not arise from
differences in body fat distribution. These findings,
like any observational studies, suffer from two
major limitations. Firstly, both cohorts we used
might be subject to ‘healthy volunteer’ selection
bias; and secondly, neither of the cohorts are fully
representative of their original populations.
There is a genetic predisposition for adipose tissue expandability
and fat storage capacity
Recent large-scale GWASs have provided evidence
that a number of genetic variants implicate a
paradoxically inverse relationship between adipos-
ity and risk of cardiometabolic disease [81-86]. In
the most recent study, we identified 14 genetic
variants where the adiposity-increasing alleles
were associated with a favourable metabolic profile
and lower risk of type 2 diabetes, heart disease and
hypertension (Table 2). These alleles were named
as ‘favourable adiposity’ alleles as people carrying
the greatest number have increased adiposity
(higher body fat % and BMI), but paradoxically a
reduced frequency of metabolic complications of
obesity compared to noncarriers. For example, the
10% of subjects carrying the greatest number of
favourable adiposity alleles had 1.04% higher
Fig. 2 Transverse slices of 4 participants from abdominal MRI measures. Intensity-corrected fat image using overlay
colours illustrates how two people with same BMI or waist circumference, same age and gender can have very different
levels of subcutaneous and visceral fat and therefore, different disease risk.
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body fat % and 0.4 kg m2 higher BMI but almost
half risk of type 2 diabetes compared with the 10%
of subjects carrying the fewest favourable adiposity
alleles. Analysis of MRI based imaging data pro-
vided an important explanatory mechanism
through fat distribution: the favourable adiposity
alleles were associated with no differences in
visceral fat, but higher subcutaneous and lower
liver fat [81] (Fig. 3).
Effective fat storage in subcutaneous adipose tis-
sue would separate potential detrimental lipids
from ectopic fat storage or reduce lipotoxicity in
cells or tissues lacking dedicated fat storage capac-
ity. Amongst many possible mechanisms underly-
ing this specific aetiology is the ability to generate
new adipocytes. Adipocytes expand to store circu-
lating free fatty acids postmeals in the form of
triglycerides. This expansion occurs by the
enlargement of pre-existing adipocytes (hypertro-
phy) or by generating new small adipocytes (hy-
perplasia), or both [87]. The expansion in the form
of size or hypertrophy correlates with higher fasting
insulin, insulin resistance and higher risk of type 2
diabetes [88,89]. Obese subjects with few large
adipocytes are more glucose intolerant and hyper-
insulinemic than those having the same degree of
obesity but many small adipocytes [88,89].
Our initial results from more than 160 subcuta-
neous fat biopsies provide evidence that three
favourable adiposity variants (in or near PPARG,
KLF14 and FAM13A) are linked with adipose tissue
function [90]. These results indicate that adiposity-
increasing alleles at these variants possibly protect
from type 2 diabetes by increasing the pool of small
adipocytes in the subcutaneous fat depots. For
other favourable adiposity variants, it is not known
which genes they are acting through; however, the
nearest genes are enriched in mechanisms related
to adipogenesis and adipocyte differentiation (IRS1,
DNAH10 and CCDC92), insulin signalling
(FAM13A), adipose tissue maintenance (TRIB1),
triglycerides lipase (LYPLAL1) and insulin sensitiv-
ity (GRB14), all mainly expressed in subcutaneous
adipose tissue.
The pattern of association between favourable
adiposity variants and adiposity, subcutaneous
and ectopic fat and risk of type 2 diabetes is
consistent with the ‘adipose tissue expandability’
hypothesis [91]. Type 2 diabetes occurs as a result
of the inability of the adipose tissue to expand and
accommodate excess fat following extra calories
independent of total adiposity [92]. In fact, genetics
of favourable adiposity provides evidence that there
is a genetic predisposition for adipose tissue
expandability and the fat storage capacity may be
in part genetically determined. If individuals are
able to sufficiently expand their subcutaneous
adipose tissue, they will be protected, to some
extent, against the adverse effects of higher adi-
posity and have a normal metabolic profile despite
considerable increase of their adipose tissue mass
(Fig. 4).
Can genetics of favourable adiposity tell us about the ethnic
difference in risk of type 2 diabetes?
Now the question is whether the genetic variants
associated with favourable adiposity within Euro-
peans have similar paradoxical association with
adiposity and risk of diabetes in other ethnic
groups. The unpublished results using genetic
data from 10 700 South Asian individuals in the
UK Biobank study indicates that favourable adi-
posity alleles have similar effect as seen in Euro-
peans [93]. Comparison of the allele frequencies,
however, has revealed that South Asians living in
the UK have fewer of these protective alleles
compared to white European participants in the
UK Biobank study. This genetic difference could
partly explain the differences in body fat distribu-
tion and its relationship with disease in South
Asian. This ethnic group appears to carry a smaller
number of alleles that are associated with the
ability to store extra fat in a safe place which is
subcutaneous adipose tissue.
There are very few observational studies investi-
gated the cellular characteristics of adipose tissue
across ethnicities but their results are consistent
with our finding about the low frequency of
favourable adiposity alleles in South Asians. Com-
pared to white Europeans, South Asian men and
women have been shown to have larger adipocytes
[94]. The study of type 2 diabetes risk factors in
obese Pima Indians indicated the best predictive
factor for the onset of diabetes was adipocyte size
independent of age, sex and body fat percentage,
suggesting difficulty in differentiating new adipo-
cytes plays an important role in disease mecha-
nism [95].
Although these findings may partly explain the
excess prevalence of type 2 diabetes in South
Asians, it is very important to study the effect and
frequencies of these genetic variants in other ethnic
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groups. The discovery of favourable adiposity vari-
ants was originally made in populations of Euro-
pean descent and therefore may not adequately
capture genetic variation in individuals of non-
European descent. Furthermore, the allelic archi-
tecture of favourable adiposity may differ for
African, native American and Asians versus Euro-
peans.
Type 2 diabetes, a disease with a heterogeneous spectrum of
metabolic disturbance
Insulin resistance and insulin secretory failure are
two well-established characteristics of type 2
diabetes. Insulin resistance may initially be com-
pensated by increased insulin secretion, and pro-
gression to type 2 diabetes is thought to occur
when beta-cells are unable to compensate to a
sufficient degree. However, type 2 diabetes is a
multisystem disease which involves abnormalities
in the pancreas, fat, muscle, liver and, probably,
the brain. Despite the huge enthusiasm and exten-
sive effort to identify distinct subtypes for type 2
diabetes, there is an increasing body of evidence
from GWAS studies supporting the concept that
considerable variation exists in the phenotype of
individuals with type 2 diabetes not only across
ethnic groups but also within each ethnic group.
Table 2. Genetic variants associated with favourable adiposity
SNP ID Chromosome Position
Nearest
gene
Function of the nearest
gene
Is there an association between the
SNP and the nearest gene expression
in adipose tissue?
rs11118306 1 219627486 LYPLAL1 Triglyceride lipase
rs13389219 2 165528876 GRB14 Adipogenesis, lipid
metabolism, and
insulin signalling
Yes
rs2943653 2 227047771 IRS1 Adipogenesis, lipid
metabolism, and
insulin signalling
Yes
rs1801282 3 12393125 PPARG Master transcriptional
regulator of adipocyte
differentiation
Yes
rs2276936 4 89726283 FAM13A Adipose development
and insulin sensitivity
Yes
rs40271 5 55796319 ANKRD55
rs632057 6 139834012 CITED2 Yes
rs998584 6 43757896 VEGFA
rs972283 7 130466854 KLF14 Master regulator of gene
expression in adipose
tissue
rs2980888 8 126507308 TRIB1 Adipose tissue
maintenance
rs7133378 12 124409502 DNAH10 Adipogenesis/adipocyte
differentiation
Yes
rs11045172 12 20470221 AEBP2
rs7258937 19 33938800 PEPD Adipogenesis, lipid
metabolism, and
insulin signalling
Yes
rs2267373 22 38600542 MAFF Yes
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Based on data from clinical, biochemical, immuno-
logical, anthropometric and, more importantly,
genetic measures, it seems more probable that
individuals develop type 2 diabetes due to a
combination of defects in multiple pathways albeit
to a different degree. This concept was introduced
by McCarthy as the palette model of diabetes [96].
In this model, different ‘base colours’ represent
pathophysiological pathways which in combina-
tion, but with different degrees of contribution,
transport individuals in a journey from health to
diabetes (Fig. 1). These pathways include beta-cell
development, size, and function, islet autoimmu-
nity, incretin activity, obesity, fat distribution,
adipose tissue dysfunction, insulin resistance and
many other mechanisms that are still unknown
3.6 x 10–45
6 x 10–263
2 x 10–14
2 x 10–14 5.6 x 10–6
3 x 10–14 1 x 10–33
4 x 10–44
(a)
(b)
Fig. 3 The effect of ‘favourable adiposity’ genetic score on (a) measures of adiposity, MRI abdominal fat distribution and
(b) cardiometabolic disease risk. Data from Ji et al (81). Effects are per carrying 5 additional adiposity-increasing alleles.
Red box shows p-value for the association.
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[96]. As shown in Fig. 1, the palette model illus-
trates a colour for each individual based on
contribution of each ‘base colour’ (pathophysiolog-
ical pathway).
With inconclusive evidence from studies which try
to unravel the mystery of ethnic difference in risk of
type 2 diabetes, it seems reasonable to consider the
palette model in study design and also interpreta-
tion of results. With the exception of isolated
populations, where common genetic variants
impair a distinct pathway and explain a large
proportion of disease risk, in majority of popula-
tions, type 2 diabetes is indeed a complex polygenic
disease, where multiple common low-impact risk
variants contribute to the disease mechanism.
To understand the impact and role of each pathway
in different populations, it makes more sense to
design a multiomic approach by measuring (i)
genetic variants associated with each pathway
(e.g. beta-cell function, obesity, lipodystrophy and
disrupted liver lipid metabolism) and (ii) interme-
diate phenotypes as captured by transcriptome,
proteome or metabolome. If the degree of patho-
genesis differs based on ethnicity, one would
expect to see enrichment of different ‘base col-
ours’ in different ethnic groups.
Summary
Our current knowledge on genetic architecture of
type 2 diabetes is Eurocentric where more than
55% of samples are from white European ethnicity
whereas majority of people with type 2 diabetes are
of non-European ethnicity. The comparatively lim-
ited number of non-European GWASs have been
very successful in providing insights about the
disease mechanisms and drug targets but they
have not been effective in identifying mechanisms
that make non-European more susceptible to
higher risk of disease. It is expected that comple-
tion of large-scale GWASs and whole genome/
exome sequencing in non-Europeans provide more
resolution about the disease mechanism in these
populations. Since type 2 diabetes is driven by not
only genetic variation but also by variation in
different environmental exposures, any ethnic-
specific contribution of genetic background to
individual predisposition needs to be merged with
information on internal (e.g. microbiome) as well as
the external (e.g. lifestyle) environment.
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